Cetuximab dose-escalation study in patients with metastatic colorectal cancer with no or slight skin
reactions on cetuximab dose treatment (EVEREST): pharmacokinetic and efficacy data of a …

Background This phase I dose-escalation study was designed to determine the maximum
tolerated dose (MTD) and recommended dose of cetuximab administered on an every …

Purpose This phase II study investigated the efficacy and safety of cetuximab combined with
standard oxaliplatin-based chemotherapy (infusional fluorouracil, leucovorin, and oxaliplatin …

Purpose This was an open, randomized, multicenter, phase I/II study to investigate the safety
and tolerability of cetuximab in the first-line treatment of recurrent/metastatic squamous cell …

Background The anti-epidermal growth factor receptor (EGFR) antibody cetuximab is active
in heavily pretreated patients with metastatic colorectal cancer (mCRC) both in monotherapy …

Abstract Learning Objectives Compare survival outcomes among patients with SCCHN
treated with a platinum/5‐FU regimen with and without cetuximab. Compare adverse event …

Abstract▴ Cetuximab is a chimeric monoclonal antibody highly selective for the epidermal
growth factor receptor (EGFR), which is over-expressed by 25–80% of colorectal cancer …

Purpose: The epidermal growth factor receptor (EGFR), a protein tyrosine kinase expressed
in many types of human cancers including colon and breast, has been strongly associated …

Since its introduction, the use of cetuximab in the treatment of head and neck squamous cell
carcinoma (HNSCC) has experienced an evolution. Currently, cetuximab associated with …

The epidermal growth factor receptor (EGFR) plays an essential role in normal cell growth
and differentiation and in the survival of healthy and cancerous cells. EGFR expression is a …